Yuchun Lee - 27 Jan 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
27 Jan 2023
Net transactions value
-$357,089
Form type
4
Filing time
31 Jan 2023, 15:42:11 UTC
Previous filing
27 Jan 2023
Next filing
03 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $103,088 +1,429 +76% $72.14 3,304 27 Jan 2023 Direct
transaction VRTX Common Stock Sale $121,776 -379 -11% $321.31 2,925 27 Jan 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $312,534 -970 -33% $322.20 1,955 27 Jan 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $25,866 -80 -4.1% $323.33 1,875 27 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1,429 -100% $0.000000* 0 27 Jan 2023 Common Stock 1,429 $72.14 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
F2 Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $321.31 (range $320.62 to $321.59).
F4 Open market sales reported on this line occurred at a weighted average price of $322.20 (range $321.75 to $322.74).
F5 Fully vested.